The latest issue of NPS RADAR
features a review of dapagliflozin
(Forxiga) and canagliflozin
(Invokana) which are listed on the
PBS from Dec 1.
These are the first PBS-listed
medicines from a new class of oral
anti-diabetics, the sodium-glucose
co-transporter 2 (SGLT2) inhibitors.
December’s NPS RADAR
also includes in-depth reviews
of fluticasone propionate
with eformoterol fumarate
(Flutiform) for asthma,
olmesartan with amlodipine and
hydrochlorothiazide (Sevikar HCT),
a triple fixed-dose combination
for hypertension and Ivabradine
(Coralan) for chronic heart failure.
Go to www.nps.org.au/radar for
details of the reviews.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.